GGrantIndex
← Leaderboards

Stephanie Duggins Davis

Seattle Children'S Hospital

$6,278,112
Attributed
$13,719,979
Total exposure
11
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.5M · FY200823
$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$21,214,399 · 12

By mechanism

U54$9,279,794 · 4
R01$8,485,933 · 3
U01$2,026,286 · 1
T32$1,377,386 · 2
R13$45,000 · 2

Most similar at Seattle Children'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Respiratory

Research focus

RespiratoryLung DiseasesClinical TrialsChronicMucociliary ClearanceBaseMorbidity - Disease RateAdultDiagnosisResearch PersonnelChildLungAffectMeasurementFunctional DisorderLeadPrimary Ciliary DyskinesiasDefectCongenital ImmunodeficiencyGenetic DiseasesInfantFutureNoseOutcome Measure

Grant awards (39)

Genetic Disorders of Mucociliary Clearance$1,448,157
U54 · FY2023 · HL · contact PI
Characterizing the upper airway manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies$217,023
U54 · FY2023 · HL · contact PI
GDMCC Administrative Core$134,883
U54 · FY2023 · HL · contact PI
Genetic Disorders of Mucociliary Clearance$1,461,652
U54 · FY2022 · HL · contact PI
Characterizing the upper airway manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies$217,335
U54 · FY2022 · HL · contact PI
GDMCC Administrative Core$135,557
U54 · FY2022 · HL · contact PI
Pediatrics & Pulmonary Network: Improving Health Together$30,000
R13 · FY2022 · HL · contact PI
Genetic Disorders of Mucociliary Clearance$1,471,263
U54 · FY2021 · HL · contact PI
Characterizing the upper airway manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies$218,490
U54 · FY2021 · HL · contact PI
GDMCC Administrative Core$137,722
U54 · FY2021 · HL · contact PI
Genetic Disorders of Mucociliary Clearance$1,487,339
U54 · FY2020 · HL · contact PI
Characterizing the upper airway manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies$220,333
U54 · FY2020 · HL · contact PI
GDMCC Administrative Core$140,726
U54 · FY2020 · HL · contact PI
Genetic Disorders of Mucociliary Clearance$1,626,009
U54 · FY2019 · HL · contact PI
Characterizing the upper airway manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies$232,608
U54 · FY2019 · HL · contact PI
GDMCC Administrative Core$130,697
U54 · FY2019 · HL · contact PI
IU training Program in Molecular Physiology and Clinical Mechanisms of Lung Disea$331,065
T32 · FY2017 · HL · contact PI
IU training Program in Molecular Physiology and Clinical Mechanisms of Lung Disea$2,160
T32 · FY2017 · HL · contact PI
IU training Program in Molecular Physiology and Clinical Mechanisms of Lung Disea$322,369
T32 · FY2016 · HL · contact PI
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease$531,756
R01 · FY2015 · HL · contact PI
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia$452,970
R01 · FY2015 · HL
IU training Program in Molecular Physiology and Clinical Mechanisms of Lung Disea$315,340
T32 · FY2015 · HL · contact PI
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia$613,729
R01 · FY2014 · HL
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease$530,129
R01 · FY2014 · HL · contact PI
Predictive Modeling for Treatment of Upper Airway Obstruction in Young Children$823,090
R01 · FY2013 · HL · contact PI
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia$607,404
R01 · FY2013 · HL
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease$523,412
R01 · FY2013 · HL · contact PI
Predictive Modeling for Treatment of Upper Airway Obstruction in Young Children$879,906
R01 · FY2012 · HL · contact PI
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia$628,143
R01 · FY2012 · HL
Viral Pathogenesis of Early Cystic Fibrosis Lung Disease$605,339
R01 · FY2012 · HL · contact PI
Multidisciplinary research training in pulmonary diseases$406,452
T32 · FY2012 · HL
Predictive Modeling for Treatment of Upper Airway Obstruction in Young Children$915,508
R01 · FY2011 · HL · contact PI
Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia$478,477
R01 · FY2011 · HL
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) - CCC - Lead Application$443,348
U01 · FY2011 · HL
Predictive Modeling for Treatment of Upper Airway Obstruction in Young Children$896,070
R01 · FY2010 · HL · contact PI
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) - CCC - Lead Application$517,638
U01 · FY2010 · HL
Primary Ciliary Dyskinesia and Overlapping Syndromes$15,000
R13 · FY2010 · HL · contact PI
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) - CCC - Lead Application$533,626
U01 · FY2009 · HL
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) - CCC - Lead Application$531,674
U01 · FY2008 · HL